Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308976654> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4308976654 endingPage "vii82" @default.
- W4308976654 startingPage "vii82" @default.
- W4308976654 abstract "Abstract BACKGROUND TTFields plus Temozolomide (TTFields/TMZ) extended survival versus TMZ alone in newly diagnosed glioblastoma (GBM) patients in the EF-14 trial. We report a retrospective analysis of Chinese newly diagnosed GBM patients who received TTFields combine with TMZ treatment and traditional TMZ monotherapy from May 2019 to May 2021 in Shanghai Hua Shan hospital.METHOD: Overall survival (OS) and progression-free survival (PFS) curves were constructed using the Kaplan-Meier method. A Cox proportional hazards regression model with inverse probability of treatment weighting (IPTW) based on propensity score was used to assess the effect of TTFields and account for confounding factors. RESULT: In the preliminary analysis, the PFS in the TTFields/TMZ arm was 16 months (95% CI:9.6–24.6) versus 11 (95% CI: 9–12) with TMZ alone (p ＜0.05). Median overall survival was 21.8 months (95% CI 17.4-NA) with TTFields/TMZ versus 15 months (95% CI 13–18; HR 0.43, p ＜0.01) with TMZ alone. In the Multivariate analysis, Surgery type, STUPP scheme, IDH status, and TTFields use were identified as favorable prognostic factors. After PSM adjustment, the groups were similar, except that MGMT promoter methylation remained more in the TMZ group (12 v 32; P = 0.011). Upon IPTW Survival analysis, TTFields was associated with a significantly lower risk of death (hazard ratio [HR], 0.19 in OS (95% CI 0.09–0.41) and progression (HR, 0.35 (95% CI 0.14–0.91) compared with TMZ alone. CONCLUSION In the analysis of our single center of patients with glioblastoma, the addition of TTFields to maintenance temozolomide chemotherapy vs maintenance temozolomide alone, resulted in statistically significant improvement in progression-free survival and overall survival. These results are consistent with the outcome of EF-14." @default.
- W4308976654 created "2022-11-20" @default.
- W4308976654 creator A5029003093 @default.
- W4308976654 creator A5031430573 @default.
- W4308976654 creator A5047799581 @default.
- W4308976654 creator A5055355902 @default.
- W4308976654 creator A5057474860 @default.
- W4308976654 creator A5063927571 @default.
- W4308976654 creator A5091800151 @default.
- W4308976654 date "2022-11-01" @default.
- W4308976654 modified "2023-10-16" @default.
- W4308976654 title "CTNI-47. TUMOR TREATING FIELDS COMBINE WITH TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS OF CHINESE PATIENTS" @default.
- W4308976654 doi "https://doi.org/10.1093/neuonc/noac209.312" @default.
- W4308976654 hasPublicationYear "2022" @default.
- W4308976654 type Work @default.
- W4308976654 citedByCount "0" @default.
- W4308976654 crossrefType "journal-article" @default.
- W4308976654 hasAuthorship W4308976654A5029003093 @default.
- W4308976654 hasAuthorship W4308976654A5031430573 @default.
- W4308976654 hasAuthorship W4308976654A5047799581 @default.
- W4308976654 hasAuthorship W4308976654A5055355902 @default.
- W4308976654 hasAuthorship W4308976654A5057474860 @default.
- W4308976654 hasAuthorship W4308976654A5063927571 @default.
- W4308976654 hasAuthorship W4308976654A5091800151 @default.
- W4308976654 hasBestOaLocation W43089766541 @default.
- W4308976654 hasConcept C10515644 @default.
- W4308976654 hasConcept C126322002 @default.
- W4308976654 hasConcept C143998085 @default.
- W4308976654 hasConcept C167135981 @default.
- W4308976654 hasConcept C17923572 @default.
- W4308976654 hasConcept C187960798 @default.
- W4308976654 hasConcept C207103383 @default.
- W4308976654 hasConcept C2776194525 @default.
- W4308976654 hasConcept C2776694085 @default.
- W4308976654 hasConcept C2777389519 @default.
- W4308976654 hasConcept C44249647 @default.
- W4308976654 hasConcept C502942594 @default.
- W4308976654 hasConcept C50382708 @default.
- W4308976654 hasConcept C71924100 @default.
- W4308976654 hasConcept C77350462 @default.
- W4308976654 hasConceptScore W4308976654C10515644 @default.
- W4308976654 hasConceptScore W4308976654C126322002 @default.
- W4308976654 hasConceptScore W4308976654C143998085 @default.
- W4308976654 hasConceptScore W4308976654C167135981 @default.
- W4308976654 hasConceptScore W4308976654C17923572 @default.
- W4308976654 hasConceptScore W4308976654C187960798 @default.
- W4308976654 hasConceptScore W4308976654C207103383 @default.
- W4308976654 hasConceptScore W4308976654C2776194525 @default.
- W4308976654 hasConceptScore W4308976654C2776694085 @default.
- W4308976654 hasConceptScore W4308976654C2777389519 @default.
- W4308976654 hasConceptScore W4308976654C44249647 @default.
- W4308976654 hasConceptScore W4308976654C502942594 @default.
- W4308976654 hasConceptScore W4308976654C50382708 @default.
- W4308976654 hasConceptScore W4308976654C71924100 @default.
- W4308976654 hasConceptScore W4308976654C77350462 @default.
- W4308976654 hasIssue "Supplement_7" @default.
- W4308976654 hasLocation W43089766541 @default.
- W4308976654 hasOpenAccess W4308976654 @default.
- W4308976654 hasPrimaryLocation W43089766541 @default.
- W4308976654 hasRelatedWork W1600263780 @default.
- W4308976654 hasRelatedWork W1997539222 @default.
- W4308976654 hasRelatedWork W2056185445 @default.
- W4308976654 hasRelatedWork W2136543019 @default.
- W4308976654 hasRelatedWork W2584343805 @default.
- W4308976654 hasRelatedWork W2736518463 @default.
- W4308976654 hasRelatedWork W2912909642 @default.
- W4308976654 hasRelatedWork W3021272956 @default.
- W4308976654 hasRelatedWork W4315619496 @default.
- W4308976654 hasRelatedWork W4381716024 @default.
- W4308976654 hasVolume "24" @default.
- W4308976654 isParatext "false" @default.
- W4308976654 isRetracted "false" @default.
- W4308976654 workType "article" @default.